Dr. Matthew Gdovin and Tom Roberts interviewed on the “Answers for the Family” radio show
VITANOVA BIOMEDICAL LIVE INTERVIEW September 21, 2020
(SAN ANTONIO, Texas) – Vitanova Biomedical discusses their light-activated targeted cancer therapy live on the “Answers for the Family” radio show. Watch and Listen.
Vitanova Biomedical partners with Optimize Capital Markets Exchange (OCMX)
VITANOVA BIOMEDICAL NEWS September 8, 2020
(SAN ANTONIO, Texas) – Vitanova Biomedical partners with Optimize Capital Markets Exchange (OCMX) to facilitate the raising of their Seed round of financing. Read More.
Vitanova Biomedical Awarded Competitive Grant from the National Science Foundation
VITANOVA BIOMEDICAL PRESS RELEASE August 27, 2020
(SAN ANTONIO, Texas) – Vitanova Biomedical receives seed funding for R&D from the National Science Foundation (NSF) Small Business Innovation Research (SBIR) program. Read More.
Vitanova Biomedical and LiteCure Medical Lasers announce a global strategic partnership
VITANOVA BIOMEDICAL PRESS RELEASE June 23, 2020
(SAN ANTONIO, Texas) – Vitanova Biomedical and LiteCure Medical Lasers are pleased to announce a global strategic partnership, combining Vitanova Biomedical’s light-activated cancer drug with LiteCure’s advanced laser technology. Read More.
Vitanova Biomedical enters partnership with the National Foundation for Cancer Research
VITANOVA BIOMEDICAL PRESS RELEASE November 15, 2019
(SAN ANTONIO, Texas) – Vitanova Biomedical is a “Featured Startup” of the AIM-HI Accelerator Fund. The AIM-HI Fund, launched by the National Foundation for Cancer Research, represents a paradigm shift in accelerating disruptive innovations in cancer prevention, treatment and care from the laboratory bench to the bedside. Read More.
Vitanova Biomedical is awarded Top Prize at the Houston InnoSTARS Competition
U.S. CHINA INNOVATION ALLIANCE PRESS RELEASE May 19, 2019
(Houston, Texas) – Vitanova Biomedical, Inc. was awarded Top Prize in the category of Biopharma, Medical Device, Digital Health and Diagnosis at U.S. China Innovation Alliance’s InnoSTARS Competition in Houston, TX. As winner’s, Vitanova Biomedical will be traveling to China in Q3, 2019 to compete in the industry final. Read More.
Matthew Gdovin, Ph.D. to Present at the 2nd International Prostate Cancer Symposium and Inaugural World Congress of Urologic Satellite Session
VITANOVA BIOMEDICAL PRESS RELEASE September 1, 2017
(SAN ANTONIO, Texas) – Matthew Gdovin, Ph.D., University of Texas – San Antonio Professor and Chief Science Officer of Vitanova Biomedical, the San Antonio, Texas-based biotech company dedicated to delivering transformative cancer therapy utilizing their patented Light-Activated Intracellular Acidosis (LAIA) platform technology, will present at the 2nd International Prostate Cancer Symposium and Inaugural World Congress of Urologic Oncology being held September 6-9, 2017 in New York, NY. Read More.
JOURNAL OF CLINICAL ONCOLOGY June 6, 2016
Breast cancer, though much researched, continues to claim the lives of more than half a million women worldwide each year; triple negative breast cancer (TNBC) accounts for 15-25% of these mortalities. Treatment options for TNBC are limited to surgery, radiation, and a select few chemotherapies, to which the cancer often becomes resistant. Cancer cells maintain a more basic intracellular pH (pHi ) than healthy cells, making disruption of pH dynamics a potential target for treatment. Read More.
THE RIVARD REPORT February 22, 2016
The excitement in the lab was palpable as Dr. Matthew Gdovin, associate professor in the Department of Biology at UTSA, described the ground-breaking research that may change the way we treat cancer. This new treatment, Photodynamic Therapy, causes no side effects and is effective in killing some of the most difficult to cure cancers. Read More.
SCIENCE DAILY June 27, 2016
A newly patented method to kill cancer cells has been developed by an American lab. This discovery may tremendously help people with inoperable or hard-to-reach tumors, as well as young children stricken with cancer. Read More.